RALEIGH, N.C., June 10 /PRNewswire/ -- CLOSURE Medical Corporation
(Nasdaq: CLSR) today announced the appointment of William M. Cotter to the
position of Vice President - Manufacturing and Operations reporting directly
to President and Chief Executive Officer Robert V. Toni.
    Mr. Cotter, who has over 20 years of manufacturing experience in the
medical devices and other industries, joins CLOSURE from Sanofi Diagnostic
Pasteur, Inc, where he spent the last eight years as Vice President of
Operations.  During his tenure there, he was instrumental in instituting
Sanofi's Continuous Process Improvement operating strategy.
    Prior to joining Sanofi Diagnostic, Mr. Cotter worked with Bristol-Myers
Squibb Company for eight years, holding positions of increasing responsibility
both domestically and internationally.
    Commenting on Mr. Cotter's appointment, Mr. Toni said, "We are extremely
pleased that Bill is joining our senior staff.  He has an unusual mix of large
and small company experience, and combines valuable expertise in the health
care industry with a broad perspective in high tech manufacturing processes.
His skills and experience will be a valuable asset to CLOSURE, particularly as
we prepare for the European launch of our Dermabond product."
    CLOSURE Medical develops, commercializes and manufactures medical cohesive
products based on its proprietary cyanoacrylate technology.  CLOSURE's
nonabsorbable products may be used to replace sutures and staples for certain
topical wound closure applications, while its absorbable products can
potentially be used as surgical sealants and adhesives for internal wound
closure and management.  Currently marketed products include Octyldent, used
in conjunction with antibiotics to treat adult periodontal disease, and
Nexaband, a line of topical adhesives used in veterinary wound closure and
management.

    To receive CLOSURE's latest news release and other corporate documents via
FAX -- at no cost -- dial 1-800-PRO-INFO.  Use Company's ticker-CLSR.

    This release contains certain forward-looking statements which involve
known and unknown risks, delays, uncertainties or other factors not under the
Company's control which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance, or
other expectations implied by these forward-looking statements.  These factors
include, but are not limited to, those detailed in the Company's Prospectus
dated September 25, 1996 filed with the Securities and Exchange Commission and
the early stage of commercialization of the Company's products; the need for
regulatory approval and effects of governmental regulation; technological
uncertainties; dependence on marketing partners; and dependence on patents and
trade secrets.

Link to this page: